Thormason Yanagi, MD in Fresno, CA - Anesthesiology

Thormason Yanagi, MD is a Anesthesiology physician based in Fresno, California. Thormason Yanagi is licensed to practice in California (license number A37854) and his current practice location is 1303 E Herndon Ave, Fresno, California. He can be reached at his office (for appointments etc.) via phone at (559) 450-3000.

NPI number for Thormason Yanagi is 1174555643 and his current mailing address is 7417 N Cedar Ave, Fresno, California. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1174555643.

Contact Information

	Thormason Yanagi, MD
	1303 E Herndon Ave, Fresno, CA 93720-3309
	(559) 450-3000
	Not Available

Physician's Profile

Full Name	Thormason Yanagi
Gender	Male
Speciality	Anesthesiology
Location	1303 E Herndon Ave, Fresno, California
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1174555643
Provider Enumeration Date: 07/07/2006
Last Update Date: 09/21/2011

Medical Identifiers

Medical identifiers for Thormason Yanagi such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1174555643	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207L00000X	Anesthesiology	A37854 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Thormason Yanagi is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Thormason Yanagi, MD 7417 N Cedar Ave, Fresno, CA 93720-3637 Ph: (559) 436-0871	Thormason Yanagi, MD 1303 E Herndon Ave, Fresno, CA 93720-3309 Ph: (559) 450-3000

News Archive

Firmenich SA decides to continue with commercial development of S6973

Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Firmenich SA, the world's largest privately-owned fragrance and flavor company, has made a decision to proceed with commercial development of S6973, Senomyx's enhancer of sucrose (table sugar) that has demonstrated the ability to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.

Tea helps promote weight loss and improve bone health

Decades worth of research shows that tea-the second most consumed beverage in the world-may help prevent chronic illnesses, including heart disease, certain types of cancer and type 2 diabetes. New research shows tea has been found to help promote weight loss and maintain a healthy weight, improve bone health and activate areas of the brain that bolster attention, problem solving and mood.

New study: Women with early stage breast cancer worry about recurrence

A new study has found that certain types of women with early stage breast cancer are vulnerable to excessive worrying about cancer recurrence. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also indicates that worrying about cancer recurrence can compromise patients' medical care and quality of life.

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Boehringer Ingelheim today announced data from the landmark RE-LY® study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% (p<0.001) in patients with atrial fibrillation compared to well-controlled warfarin without increasing the risk of major bleeding.

MMI-USA announces limited launch of new Smart Toe II Hammertoe Fixation System

MMI-USA, a subsidiary of Memometal Technologies S.A., a global orthopaedic manufacturer headquartered in France, announces the limited launch of the new Smart Toe® II Hammertoe Fixation System. The product becomes an important piece of a comprehensive system for forefoot fixation, and reinforces the most widely used franchise of intramedullary implants of this kind in the world.

Anesthesiology Doctors in Fresno, CA

William B Etiz, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1303 E Herndon Ave, Fresno, CA 93720 Phone: 559-450-3000
Mr. James J Plunkett, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7055 N Fresno St, Fresno, CA 93720 Phone: 559-449-9977
Yang J Kim, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1303 E Herndon Ave, Fresno, CA 93720 Phone: 559-450-3000
John S Sturman, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1303 E Herndon Ave, Fresno, CA 93720 Phone: 559-450-3000
Gregory Alan Smith, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 5680 N Fresno St Ste 105, Fresno, CA 93710 Phone: 559-374-5130 Fax: 888-977-4918
Rasheed Amireh, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1630 E Herndon Ave, Fresno, CA 93720 Phone: 559-447-1432 Fax: 559-432-2874
Andre S Motie, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1303 E Herndon Ave, Fresno, CA 93720 Phone: 559-450-3000

Thormason Yanagi, MD - Anesthesiology in Fresno, CA